Japan Diabetes Drugs and Devices Market Growth, Size, Trends, Share, Demand and Future Outlook
Japan Diabetes Drugs and Devices Market Size- By Drugs, By Devices, By Monitoring Devices- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Jul-2024 | Report ID: MEDE2439 | Pages: 1 - 107 | Formats*: |
| Category : Medical Devices | |||
Japan Diabetes Drugs and Devices Market Introduction and Overview
According to SPER Market Research, the Japan Diabetes Drugs and Devices Market is estimated to reach USD 7.8 billion by 2033 with a CAGR of 6.8%.
The report includes an in-depth analysis of the Japan Diabetes Drugs and Devices Market, including market size and trends, product mix, applications, and supplier analysis. Diabetes Drugs and Devices are there as the hormone insulin produced by the pancreas regulates blood glucose levels. Diabetes arises when the body is unable to produce enough insulin to control blood glucose levels. Diabetes care devices are used to check blood glucose levels. Patients with diabetes use a continuous glucose monitor as a piece of equipment to monitor and track their blood sugar levels throughout the day. This wearable gadget may help those with diabetes monitor their blood sugar levels more easily.
- March 2023; The most recent iteration of the Health2Sync App was created by Health2Sync and incorporates insulin data from the Biocorp-developed Mallya Cap insulin cartridge, which Novo Nordisk is selling in Japan.
- September 2022; Eli Lilly's diabetic medication Mounjaro (tirzepatide) has been approved by Japan's health ministry. As per its July 2022 sales collaboration agreement with Eli Lilly Japan, Mitsubishi Tanabe Pharma Corporation distributes and sells Mounjaro in Japan. In Japan, the medication is delivered via ATEOS, a single-use autoinjector device.
Market Opportunities and Challenges
Opportunities- Diabetes is becoming more common in Japan across all age groups, and this might be linked to the country's rising obesity rate, poor eating habits, and sedentary lifestyles. Due to its high incidence, diabetes mellitus is a major concern since it places a greater financial strain on individuals, governments, and clinical systems. A few disease management initiatives run by the Japan Association for Diabetes Education and Care are part of the Japanese healthcare system. When it comes to diabetes public health initiatives, Japan is among the leaders in the Asia-Pacific area. The nation supports preventative measures that emphasize dietary and lifestyle changes that can lower the risk of adult-onset diabetes and raises public awareness of these changes.
Challenges- As diabetes is a highly prevalent condition, there is a growing global need for effective treatment alternatives. Comparably, more patients are using medicines to treat their diabetes; at the moment, there are about 60 FDA-approved medications on the market worldwide. In addition, over 100 medication candidates are being assessed globally in clinical trials for the management of diabetes. The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.
Market Competitive Landscape
The Japan Diabetes Drugs and Devices Market is a highly competitive arena due to the presence of multiple global and regional companies in the competitive environment. Leading companies in the industry are Abbott Laboratories, Dexcom, Johnson & Johnson, Medtronics, NovoNordisk, Omnipod Source, Roche, Sanofi, Tandem Diabetes Care, and Terumo Corporation, Others.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Drugs, By Devices, By Monitoring Devices |
| Regions covered | Hokkaido, Tohoku, Kanto, Chubu, Kinki Chugoku, Shikoku, Kyushu Okinawa |
| Companies Covered | Abbott Laboratories, Dexcom, Johnson & Johnson, Medtronics, NovoNordisk, Omnipod Source, Roche, Sanofi, Tandem Diabetes Care, and Terumo Corporation, Others. |
COVID-19 Impact on Japan Diabetes Drugs and Devices Market
The market for diabetes medications has been significantly impacted by the COVID-19 epidemic. As more people with COVID-19 who are hospitalized have diabetes than not, and since better glycemic control has been shown to potentially improve patient outcomes and decrease hospital stays. According to a retrospective investigation, among Japanese people, diabetes is the main risk factor for an increased severity of COVID-19 infection. As a result, the market for diabetes medications and equipment grew quickly.
Key Target Audience:
- Diabetic Patients
- Healthcare Providers
- Hospitals and Clinics
- Pharmacies
- Health Insurance Companies
- Medical Researchers and Professionals
Our in-depth analysis of the Japan Diabetes Drugs and Devices Market includes the following segments:
| By Drugs: |
|
| By Devices: |
|
| By Monitoring Devices: |
|
Key Topics Covered in the Report:
- Japan Diabetes Drugs and Devices Market Size (FY’2024-FY’2033)
- Overview of Japan Diabetes Drugs and Devices Market
- Segmentation of Japan Diabetes Drugs and Devices Market by Drugs (Insulin, Oral Anti Diabetic Drugs, Non-Insulin Injectable Drugs)
- Segmentation of Japan Diabetes Drugs and Devices Market by Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, Jet Injectors)
- Segmentation of Japan Diabetes Drugs and Devices Market by Monitoring Devices (Self-Monitoring Blood, Continuous Glucose Monitoring)
- Statistical Snap of Japan Diabetes Drugs and Devices Market
- Expansion Analysis of Japan Diabetes Drugs and Devices Market
- Problems and Obstacles in Japan Diabetes Drugs and Devices Market
- Competitive Landscape in the Japan Diabetes Drugs and Devices Market
- Impact of COVID-19 and Demonetization on Japan Diabetes Drugs and Devices Market
- Details on Current Investment in Japan Diabetes Drugs and Devices Market
- Competitive Analysis of Japan Diabetes Drugs and Devices Market
- Prominent Players in the Japan Diabetes Drugs and Devices Market
- SWOT Analysis of Japan Diabetes Drugs and Devices Market
- Japan Diabetes Drugs and Devices Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPER’s internal database2.1.4.Premium insight from KOL’s2.2.Market size estimation2.2.1.Top-down and Bottom-up approach2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges4.2.COVID-19 Impacts of the Japan Diabetes Drugs and Devices Market.
5.Market variable and outlook
5.1.SWOT Analysis5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats5.2.PESTEL Analysis5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape5.3.PORTER’s Five Forces5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Japan Diabetes Drugs and Devices Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Japan Diabetes Drugs and Devices Market
7.Japan Diabetes Drugs and Devices Market, By Drugs (USD Million) 2020-2033
7.1.Japan Diabetes Drugs and Devices Market Size, Share and Forecast, By Drugs, 2020-20267.2.Japan Diabetes Drugs and Devices Market Size, Share and Forecast, By Drugs, 2027-20337.3.Insulin7.4.Oral Anti Diabetic Drugs7.5.Non-Insulin Injectable Drugs
8.Japan Diabetes Drugs and Devices Market, By Devices (USD Million) 2020-2033
8.1.Japan Diabetes Drugs and Devices Market Size, Share and Forecast, By Devices, 2020-20268.2.Japan Diabetes Drugs and Devices Market Size, Share and Forecast, By Devices, 2027-20338.3.Insulin Pumps8.4.Insulin Pens8.5.Syringes8.6.Cartridges8.7.Jet Injectors
9.Japan Diabetes Drugs and Devices Market, By Monitoring Devices (USD Million) 2020-2033
9.1.Japan Diabetes Drugs and Devices Market Size, Share and Forecast, By Monitoring Devices, 2020-20269.2.Japan Diabetes Drugs and Devices Market Size, Share and Forecast, By Monitoring Devices, 2027-20339.3.Self-Monitoring Blood9.4.Continuous Glucose Monitoring
10.Japan Diabetes Drugs and Devices Market Forecast, 2020-2033 (USD Million)
10.1.Japan Diabetes Drugs and Devices Market Size and Market Share
11.Japan Diabetes Drugs and Devices Market, By Region, 2020-2033 (USD Million)
11.1.Japan Diabetes Drugs and Devices Market Size and Market Share By Region (2020-2026)11.2.Japan Diabetes Drugs and Devices Market Size and Market Share By Region (2027-2033)11.3.Hokkaido11.4.Tohoku11.5.Kanto11.6.Chubu11.7.Kinki11.8.Chugoku11.9.Shikoku11.10.Kyushu Okinawa
12.Company Profile
12.1.ABBOTT LABORATORIES12.1.1.Company details12.1.2.Financial outlook12.1.3.Product summary12.1.4.Recent developments12.2.DEXCOM12.2.1.Company details12.2.2.Financial outlook12.2.3.Product summary12.2.4.Recent developments12.3.JOHNSON AND JOHNSON12.3.1.Company details12.3.2.Financial outlook12.3.3.Product summary12.3.4.Recent developments12.4.MEDTRONICS12.4.1.Company details12.4.2.Financial outlook12.4.3.Product summary12.4.4.Recent developments12.5.NOVONORDISK12.5.1.Company details12.5.2.Financial outlook12.5.3.Product summary12.5.4.Recent developments12.6.OMNIPOD SOURCE12.6.1.Company details12.6.2.Financial outlook12.6.3.Product summary12.6.4.Recent developments12.7.SANOFI12.7.1.Company details12.7.2.Financial outlook12.7.3.Product summary12.7.4.Recent developments12.8. TANDEM DIABETES CARE12.8.1.Company details12.8.2.Financial outlook12.8.3.Product summary12.8.4.Recent developments12.9.TERUMO CORPORATION12.9.1.Company details12.9.2.Financial outlook12.9.3.Product summary12.9.4.Recent developments12.10.Others
13.Conclusion
14.List of Abbreviations
15.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Japan Diabetes Drugs and Devices Market is projected to reach USD 7.8 billion by 2033, growing at a CAGR of 6.8% during the forecast period.
Japan Diabetes Drugs and Devices Market grew in Market size from 2024. The Market is expected to reach USD 7.8 billion by 2033, at a CAGR of 6.8% during the forecast period.
Japan Diabetes Drugs and Devices Market CAGR of 6.8% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Japan Diabetes Drugs and Devices Market size is USD 7.8 billion from 2024 to 2033.
Japan Diabetes Drugs and Devices Market is covered By Drugs, By Devices, By Monitoring Devices
The Asia-Pacific is anticipated to have the highest Market share in the Japan Diabetes Drugs and Devices Market.
The key players in the Market include Companies Covered Abbott Laboratories, Dexcom, Johnson & Johnson, Medtronics, NovoNordisk, Omnipod Source, Roche, Sanofi, Tandem Diabetes Care, and Terumo Corporation, Others.
The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
